Research programme: antibacterials - Sepracor

Drug Profile

Research programme: antibacterials - Sepracor

Alternative Names: Antibacterials research programme - Sepracor; Quinoline-indole antibacterials research programme - Sepracor; Research programme: quinoline-indole antibacterials - Sepracor; SEP 118843; SEP 155342

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator Sepracor
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 15 May 2003 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
  • 16 Oct 2000 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top